Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Impact: Health impacts


The findings of the STAMPEDE trial changed medical practice globally. Prof Gillessen was heavily involved in this trial - a member of the trial management group, the Swiss National representative for the trial, as well sitting on the safety committee and translational committee. Additionally, Prof Gillessen is the lead for the metabolic translational group of the trial.
This paper was published in the Lancet, one of the most internationally highly regarded scientific journals.

Category of impact

  • Health impacts

Related information